mwhighlights

Highlights of MACS and WIHSProtocol and Cohorts: 

Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS Cohort Study or Women’s Interagency HIV Study

MACSPrincipal Investigators and Sites: 

MACS Principal Investigators and Sites November 2004 Charles Rinaldo, Pittsburgh Roger Detels, Los Angeles

WIHSPrincipal Investigators and Sites: 

WIHS Principal Investigators and Sites Alexandria Levine, Los Angeles Mary Young, District of Columbia Stephen Gange, WDMAC Ruth Greenblatt, San Francisco Mardge Cohen, Chicago Kathryn Anastos, Bronx Howard Minkoff, Brooklyn November 2004

Slide4: 

Password protected May 2005

Slide5: 

Behavioral - D. Ostrow Clinical - F. Palella Core Laboratory - C. Rinaldo & J. Margolick Data - L. Jacobson Malignancy/Pathology - O. Martinez-Maza Metabolic/Cardiovascular - L. Kingsley Neuropsychology - E. Miller Viral Hepatitis - C. Thio MACS Working Groups - Chairs November 2004

Slide6: 

WIHS Scientific Working Groups - Chairs Aging/Neurocognitive – M. Young Behavior/Drug Use – T. Wilson / D. Vlahov Cancer/Pathology – N. Hessol Cardiovascular – R. Kaplan Epidemiology – A. French GYN – H. Minkoff Hepatitis – M. Peters HIV Virology - B. Weiser HPV – H. Strickler Immunology - L. Al-Harthi Laboratory/Specimen – W. Meyer Metabolic – P. Tien Pharmacology - R. Greenblatt Statistical/Analytical – A. Kalinowski May 2005

MACS / WIHS Cohort: Summary: 

MACS / WIHS Cohort: Summary May 2005

Slide8: 

Semiannual Visit Medications Antivirals, OI-specific, adherence Physical Examination / GYN (WIHS) Anthropomorphic/ lipodystrophy measures Hand grip / timed walk (MACS v43.5; WIHS v22) Questionnaire / ACASI (MACS) Medical History, Health Services, Behavior Demographics / Psychosocial Quality of Life Neuropsychological Screening Specimens and Labs Plasma, Serum, Cells, CVL (WIHS), Hair (WIHS HIV+) T-cells, HIV RNA, HBV & HCV serology, lipids B-cell lines, National Repository May 2005

Slide9: 

Continuous Outcome Ascertainment Seroconversion Clinical Outcomes (medical record confirmation) AIDS diagnoses Non-AIDS diagnoses Cardiovascular disease Cerebrovascular disease Kidney disease (MACS) Liver disease Lung infection, bacterima, septicemia (MACS), TB (WIHS) Malignancies Neurologic Mortality and cause of death November 2004

Slide10: 

Descriptive Statistics May 2005

Slide11: 

MACS/WIHS Database May 2005 *Available as of 5/9/2005

Slide12: 

Demographics of MACS/WIHS Cohorts: Baseline November 2004

Slide13: 

HIV Disease Markers at Most Recent Visit: Current MACS/WIHS Cohorts November 2004

Antiretroviral Therapy Use Among Seropositives: 

Antiretroviral Therapy Use Among Seropositives Calendar Time May 2005 NRTI Monotherapy NRTI Combination Therapy HAART no PI HAART with PI MACS 0 20 40 60 80 100 1995 1997 1999 2001 2003 1995 1997 1999 2001 2003 WIHS

Slide15: 

Age Distribution among Active HIV+ MACS & WIHS Participants May 2005

Slide16: 

Age Distribution among Active HIV- MACS & WIHS Participants May 2005

HAART Use in the MACS/WIHS Cohorts: 

HAART Use in the MACS/WIHS Cohorts May 2005 96-1 97-1 98-1 99-1 00-1 01-1 02-1 03-1 04-1 0 20 40 60 80 100 Calendar (Year-Semester) Incidence of HAART per 100 P-SEM MACS Incidence Rate MACS Cumulative Incidence WIHS Incidence Rate WIHS Cumulative Incidence